Published in J Virol on March 01, 2004
Vaccinia virus H2 protein is an essential component of a complex involved in virus entry and cell-cell fusion. J Virol (2005) 1.88
Coupling viruses to dynein and kinesin-1. EMBO J (2011) 1.83
Calsyntenin-1 docks vesicular cargo to kinesin-1. Mol Biol Cell (2006) 1.53
Eclipse phase of herpes simplex virus type 1 infection: Efficient dynein-mediated capsid transport without the small capsid protein VP26. J Virol (2006) 1.53
Visualization and characterization of the intracellular movement of vaccinia virus intracellular mature virions. J Virol (2005) 1.35
Association of ebola virus matrix protein VP40 with microtubules. J Virol (2005) 1.18
Interaction between vaccinia virus extracellular virus envelope A33 and B5 glycoproteins. J Virol (2006) 1.12
Kidins220/ARMS is transported by a kinesin-1-based mechanism likely to be involved in neuronal differentiation. Mol Biol Cell (2006) 1.05
Vaccinia protein F12 has structural similarity to kinesin light chain and contains a motor binding motif required for virion export. PLoS Pathog (2010) 0.97
Making it to the synapse: measles virus spread in and among neurons. Curr Top Microbiol Immunol (2009) 0.96
A kinesin-1 binding motif in vaccinia virus that is widespread throughout the human genome. EMBO J (2011) 0.96
An E2-F12 complex is required for intracellular enveloped virus morphogenesis during vaccinia infection. Cell Microbiol (2009) 0.94
Vaccinia virus protein F12 associates with intracellular enveloped virions through an interaction with A36. J Virol (2008) 0.92
Vaccinia virus A34 glycoprotein determines the protein composition of the extracellular virus envelope. J Virol (2007) 0.89
Engineered, harnessed, and hijacked: synthetic uses for cytoskeletal systems. Trends Cell Biol (2012) 0.88
The taking of the cytoskeleton one two three: how viruses utilize the cytoskeleton during egress. Virology (2011) 0.88
Lipid membranes in poxvirus replication. Viruses (2010) 0.88
A36-dependent actin filament nucleation promotes release of vaccinia virus. PLoS Pathog (2013) 0.85
Loss of cytoskeletal transport during egress critically attenuates ectromelia virus infection in vivo. J Virol (2012) 0.82
The non-canonical roles of clathrin and actin in pathogen internalization, egress and spread. Nat Rev Microbiol (2013) 0.81
Trichoplusia ni Kinesin-1 Associates with Autographa californica Multiple Nucleopolyhedrovirus Nucleocapsid Proteins and Is Required for Production of Budded Virus. J Virol (2016) 0.78
Rho'ing in and out of cells: viral interactions with Rho GTPase signaling. Small GTPases (2014) 0.78
Increased interaction between vaccinia virus proteins A33 and B5 is detrimental to infectious extracellular enveloped virion production. J Virol (2012) 0.77
Vaccinia virus protein complex F12/E2 interacts with kinesin light chain isoform 2 to engage the kinesin-1 motor complex. PLoS Pathog (2015) 0.76
Vaccinia Virus Proteins A36 and F12/E2 Show Strong Preferences for Different KLC Isoforms. Traffic (2017) 0.75
Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science (1998) 8.51
The tetratricopeptide repeat: a structural motif mediating protein-protein interactions. Bioessays (1999) 7.89
Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J Virol (1994) 4.67
An antigenic difference between intracellular and extracellular rabbitpox virus. J Gen Virol (1971) 4.61
Assembly of vaccinia virus: role of the intermediate compartment between the endoplasmic reticulum and the Golgi stacks. J Cell Biol (1993) 4.34
The development of vaccinia virus in Earle's L strain cells as examined by electron microscopy. J Biophys Biochem Cytol (1961) 4.32
Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J Gen Virol (1980) 4.24
Actin-based motility of vaccinia virus. Nature (1995) 4.12
Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J Cell Biol (2001) 3.84
Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J Virol (1991) 3.79
The design plan of kinesin motors. Annu Rev Cell Dev Biol (1997) 3.79
Kinesin-dependent movement on microtubules precedes actin-based motility of vaccinia virus. Nat Cell Biol (2001) 3.67
Progeny vaccinia and human cytomegalovirus particles utilize early endosomal cisternae for their envelopes. Eur J Cell Biol (1993) 3.46
Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling. Nature (1999) 3.44
Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J Virol (1992) 3.24
Differences between extracellular and intracellular forms of poxvirus and their implications. Prog Med Virol (1973) 3.19
Interruption by Rifampin of an early stage in vaccinia virus morphogenesis: accumulation of membranes which are precursors of virus envelopes. J Virol (1970) 3.00
Kinesin-dependent axonal transport is mediated by the sunday driver (SYD) protein. Cell (2000) 2.96
Vaccinia virus gene A36R encodes a M(r) 43-50 K protein on the surface of extracellular enveloped virus. Virology (1994) 2.89
A complex of N-WASP and WIP integrates signalling cascades that lead to actin polymerization. Nat Cell Biol (2000) 2.72
A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology (1992) 2.67
The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology (1993) 2.66
Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. J Virol (1993) 2.64
Localization and fine structure of a vaccinia virus gene encoding an envelope antigen. J Virol (1986) 2.64
Mechanisms of viral transport in the cytoplasm. Trends Microbiol (2000) 2.63
Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J Virol (1992) 2.60
Nucleotide sequence of the vaccinia virus hemagglutinin gene. Virology (1986) 2.49
High-voltage electron microscope study of the release of vaccinia virus from whole cells. J Virol (1976) 2.39
Identification and characterization of an extracellular envelope glycoprotein affecting vaccinia virus egress. J Virol (1992) 2.35
Interaction of assembled progeny pox viruses with the cellular cytoskeleton. Virology (1979) 2.18
Vaccinia virus utilizes microtubules for movement to the cell surface. J Cell Biol (2001) 2.10
The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus. J Virol (1998) 2.05
Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. J Virol (1996) 2.03
Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J Virol (1996) 2.01
Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera. J Virol (2001) 1.98
Endoplasmic reticulum-Golgi intermediate compartment membranes and vimentin filaments participate in vaccinia virus assembly. J Virol (2002) 1.94
Vaccinia virus intracellular movement is associated with microtubules and independent of actin tails. J Virol (2001) 1.87
The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus. J Virol (1997) 1.87
Roles of vaccinia virus EEV-specific proteins in intracellular actin tail formation and low pH-induced cell-cell fusion. J Gen Virol (1998) 1.81
Grb2 and Nck act cooperatively to promote actin-based motility of vaccinia virus. Curr Biol (2002) 1.71
Role for the vaccinia virus A36R outer envelope protein in the formation of virus-tipped actin-containing microvilli and cell-to-cell virus spread. Virology (1998) 1.68
The vaccinia virus A36R protein is a type Ib membrane protein present on intracellular but not extracellular enveloped virus particles. Virology (2000) 1.56
Movements of vaccinia virus intracellular enveloped virions with GFP tagged to the F13L envelope protein. J Gen Virol (2001) 1.51
The C-terminal region of the stalk domain of ubiquitous human kinesin heavy chain contains the binding site for kinesin light chain. Biochemistry (1998) 1.47
Kinesin is essential for cell morphogenesis and polarized secretion in Neurospora crassa. EMBO J (1997) 1.46
The vaccinia virus A33R protein provides a chaperone function for viral membrane localization and tyrosine phosphorylation of the A36R protein. J Virol (2001) 1.41
Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence. J Virol (2000) 1.38
The vaccinia virus F12L protein is associated with intracellular enveloped virus particles and is required for their egress to the cell surface. J Gen Virol (2002) 1.38
A conditionally expressed third partner stabilizes or prevents the formation of a transcriptional activator in a three-hybrid system. J Biol Chem (1997) 1.20
Mapping and functional analysis of interaction sites within the cytoplasmic domains of the vaccinia virus A33R and A36R envelope proteins. J Virol (2003) 1.07
Release of vaccinia virus from FL cells infected with the IHD-W strain. J Electron Microsc (Tokyo) (1983) 1.04
Morphogenesis and release of fowlpox virus. J Gen Virol (2000) 0.92
Three-hybrid screens. Inducible third-party systems. Methods Mol Biol (2001) 0.79
A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem (2003) 3.70
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A (2003) 3.18
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A (2004) 3.08
Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions. Cell Host Microbe (2007) 2.97
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol (2003) 2.67
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
Complete pathway for protein disulfide bond formation encoded by poxviruses. Proc Natl Acad Sci U S A (2002) 2.19
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol (2002) 2.13
Poxvirus multiprotein entry-fusion complex. Proc Natl Acad Sci U S A (2005) 2.09
Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J Virol (2004) 2.06
Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J Virol (2006) 1.94
Protein composition of the vaccinia virus mature virion. Virology (2006) 1.93
Vaccinia virus H2 protein is an essential component of a complex involved in virus entry and cell-cell fusion. J Virol (2005) 1.88
Vaccinia virus A21 virion membrane protein is required for cell entry and fusion. J Virol (2005) 1.86
HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology (2006) 1.83
Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol (2007) 1.77
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Discovery of antivirals against smallpox. Proc Natl Acad Sci U S A (2004) 1.76
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis (2011) 1.76
The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all poxviruses that is required for cell entry and cell-cell fusion. J Virol (2005) 1.73
Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol (2003) 1.73
Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A (2010) 1.72
Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J Virol (2002) 1.69
Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr (2005) 1.68
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis (2011) 1.67
Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J Virol (2006) 1.63
Vaccinia virus A28L gene encodes an essential protein component of the virion membrane with intramolecular disulfide bonds formed by the viral cytoplasmic redox pathway. J Virol (2004) 1.62
Role of the I7 protein in proteolytic processing of vaccinia virus membrane and core components. J Virol (2004) 1.59
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58
External scaffold of spherical immature poxvirus particles is made of protein trimers, forming a honeycomb lattice. J Cell Biol (2005) 1.55
Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol (2003) 1.53
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology (2007) 1.52
Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology (2005) 1.49
Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein. J Virol (2006) 1.45
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol (2005) 1.44
Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology (2002) 1.44
Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci U S A (2006) 1.44
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One (2010) 1.41
Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex. J Virol (2006) 1.40
Association of vaccinia virus fusion regulatory proteins with the multicomponent entry/fusion complex. J Virol (2007) 1.40
Vaccinia virus G7L protein Interacts with the A30L protein and is required for association of viral membranes with dense viroplasm to form immature virions. J Virol (2003) 1.39
Vaccinia virus l1 protein is required for cell entry and membrane fusion. J Virol (2008) 1.39
Vaccinia virus nonstructural protein encoded by the A11R gene is required for formation of the virion membrane. J Virol (2005) 1.39
Vaccinia virus D10 protein has mRNA decapping activity, providing a mechanism for control of host and viral gene expression. Proc Natl Acad Sci U S A (2007) 1.38
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A (2008) 1.31
Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med (2007) 1.30
Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription. Proc Natl Acad Sci U S A (2003) 1.28
DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses (2004) 1.27
Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol (2009) 1.27
Vaccinia virus strain differences in cell attachment and entry. Virology (2009) 1.26
The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies. Proc Natl Acad Sci U S A (2005) 1.24
Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci U S A (2002) 1.24
Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine (2009) 1.24
SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine (2011) 1.23
Existence of an operative pathway from the endoplasmic reticulum to the immature poxvirus membrane. Proc Natl Acad Sci U S A (2006) 1.23
Characterization of a vaccinia virus mutant with a deletion of the D10R gene encoding a putative negative regulator of gene expression. J Virol (2006) 1.22
Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J Virol (2009) 1.22
Characterization of a second vaccinia virus mRNA-decapping enzyme conserved in poxviruses. J Virol (2007) 1.22
Mapping interaction sites of the A20R protein component of the vaccinia virus DNA replication complex. Virology (2002) 1.21
Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology (2004) 1.21
Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine (2007) 1.21
Expression profiling of the intermediate and late stages of poxvirus replication. J Virol (2011) 1.20
Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques. AIDS Res Hum Retroviruses (2004) 1.20
Genome-wide analysis of the 5' and 3' ends of vaccinia virus early mRNAs delineates regulatory sequences of annotated and anomalous transcripts. J Virol (2011) 1.19
Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol (2007) 1.19
Similarities in the induction of post-Golgi vesicles by the vaccinia virus F13L protein and phospholipase D. J Virol (2002) 1.18
Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology (2007) 1.16
Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses. J Virol (2009) 1.16
Identification of second-site mutations that enhance release and spread of vaccinia virus. J Virol (2002) 1.16
Degradation of host microRNAs by poxvirus poly(A) polymerase reveals terminal RNA methylation as a protective antiviral mechanism. Cell Host Microbe (2012) 1.15
Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J Infect Dis (2003) 1.15
Appraising the apoptotic mimicry model and the role of phospholipids for poxvirus entry. Proc Natl Acad Sci U S A (2009) 1.15
Vaccinia virus G4L glutaredoxin is an essential intermediate of a cytoplasmic disulfide bond pathway required for virion assembly. J Virol (2002) 1.14
Poxvirus DNA primase. Proc Natl Acad Sci U S A (2007) 1.14
Assembly and disassembly of the capsid-like external scaffold of immature virions during vaccinia virus morphogenesis. J Virol (2009) 1.14
Evidence for an essential catalytic role of the F10 protein kinase in vaccinia virus morphogenesis. J Virol (2004) 1.13
Two distinct low-pH steps promote entry of vaccinia virus. J Virol (2007) 1.13
Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models. J Virol (2010) 1.13
Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology (2006) 1.12
Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med (2008) 1.11
A conserved poxvirus NlpC/P60 superfamily protein contributes to vaccinia virus virulence in mice but not to replication in cell culture. Virology (2008) 1.10
DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology (2007) 1.09
Physical and functional interactions between vaccinia virus F10 protein kinase and virion assembly proteins A30 and G7. J Virol (2004) 1.08
A complex of seven vaccinia virus proteins conserved in all chordopoxviruses is required for the association of membranes and viroplasm to form immature virions. Virology (2004) 1.08
Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion. J Virol (2008) 1.07
Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine. J Immunol (2010) 1.07
Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. AIDS Res Hum Retroviruses (2007) 1.07